CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro.
| Institute |
|---|
| University of Birmingham |
| Cat. #: | 151431 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell signaling and signal transduction;Immunology |
| Application: | WB ; FACS ; IHC ; IF |
| Target: | Complement component (3d/Epstein Barr virus) receptor 2 (CR2, CD21) |
| Reactivity: | Human |
| Clone: | BU32 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Complement Component 3d Receptor 2; Epstein-Barr Virus Receptor 2; Complement C3d Receptor; EBV Receptor; C3DR; CD21 Antigen; CVID7; SLEB9; CD21; Cr2; CR |
|---|---|
| Product description: | CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and … |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Myeloma cell line Rob |
| Myeloma used: | NS0 |
| Target background: | CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and … |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Knapp, W. et al. eds. 1989. Leucocyte Typing IV Oxford University Press. ISBN-13: 978-0192618672 Leucocyte Typing III 1987. ISBN-13: 978-0192615527 Leucocyte Typing V 1995. ISBN-13: 978-0192623768 Leucocyte Typing VI 1998. Garland Publishing NY. ISBN-13: 978-0815327455 Ling, NR., Brown, B., Immunobiology (1992) 185(2-4) pp403-14 Jackson et al. 2020. BMC Genet. 21(1):101. PMID: 32907542. Herishanu et al. 2013. J Immunol. 190(2):784-93. PMID: 23241880. Masilamani et al. 2004. Rheumatology (Oxford). 43(2):186-90. PMID: 12867574. Aubry et al. 1992. Nature. 358(6386):505-7. PMID: 1386409. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.